Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Return on Sales (2016 - 2025)

Regenxbio (RGNX) has 12 years of Return on Sales data on record, last reported at 2.21% in Q4 2025.

  • For Q4 2025, Return on Sales rose 20.0% year-over-year to 2.21%; the TTM value through Dec 2025 reached 1.14%, up 159.0%, while the annual FY2025 figure was 1.14%, 114.0% down from the prior year.
  • Return on Sales reached 2.21% in Q4 2025 per RGNX's latest filing, down from 2.08% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.74% in Q4 2021 and bottomed at 4.06% in Q1 2024.
  • Average Return on Sales over 5 years is 2.38%, with a median of 2.44% recorded in 2024.
  • Peak YoY movement for Return on Sales: tumbled -265bps in 2022, then surged 412bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.74% in 2021, then plummeted by -359bps to 1.91% in 2022, then tumbled by -48bps to 2.83% in 2023, then increased by 15bps to 2.42% in 2024, then rose by 8bps to 2.21% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 2.21% in Q4 2025, 2.08% in Q3 2025, and 3.32% in Q2 2025.